Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center

被引：0

作者：

Raharjo, C. V. ^{[1
]}

Joseph, R. ^{[1
]}

Stratton, E. ^{[1
]}

Levy, M. ^{[1
,2
]}

Prakoso, E. ^{[1
,3
]}

机构：

[1] Liverpool Hosp, Dept Gastroenterol, Liverpool, England

[2] Univ New South Wales, Sydney, Australia

[3] Univ Sydney, Sydney, NSW, Australia

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

106

引用

下载

页码：22 / 22

页数：1

共 50 条

[41] Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data
Shimose, Shigeo
Sugimoto, Rie
Hiraoka, Atsushi
Tanaka, Masatoshi
Iwamoto, Hideki
Tanaka, Yuki
Tada, Fujimasa
Ohama, Hideko
Niizeki, Takashi
Shirono, Tomotake
Moriyama, Etsuko
Noda, Yu
Kamachi, Naoki
Nakano, Masahito
Kuromatsu, Ryoko
Koga, Hironori
Kawaguchi, Takumi
HEPATOLOGY RESEARCH, 2023, 53 (02) : 116 - 126
[42] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Mara Persano
Margherita Rimini
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
Lorenza Rimassa
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Francesco Tovoli
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Takumi Kawaguchi
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Fabio Piscaglia
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Massimo Iavarone
Giovanni Di Costanzo
Fabio Marra
Mario Scartozzi
Emiliano Tamburini
Giuseppe Cabibbo
Francesco Giuseppe Foschi
Marianna Silletta
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5591 - 5602
[43] Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Ben Khaled, Najib
Moeller, Marie
Jochheim, Leonie S.
Leyh, Catherine
Ehmer, Ursula
Boettcher, Katrin
Pinter, Matthias
Balcar, Lorenz
Scheiner, Bernhard
Weich, Alexander
Leicht, Hans Benno
Zarka, Valentina
Ye, Liangtao
Schneider, Julia
Piseddu, Ignazio
Oecal, Osman
Rau, Monika
Sinner, Friedrich
Venerito, Marino
Gairing, Simon Johannes
Foerster, Friedrich
Mayerle, Julia
Toni, Enrico N. De
Geier, Andreas
Reiter, Florian P.
JHEP REPORTS, 2024, 6 (06)
[44] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Rimassa, Lorenza
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Pressiani, Tiziana
Kawaguchi, Takumi
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Piscaglia, Fabio
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Scartozzi, Mario
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5591 - 5602
[45] Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
Ju, Shuguang
Zhou, Chen
Yang, Chongtu
Wang, Chaoyang
Liu, Jiacheng
Wang, Yingliang
Huang, Songjiang
Li, Tongqiang
Chen, Yang
Bai, Yaowei
Yao, Wei
Xiong, Bin
FRONTIERS IN ONCOLOGY, 2022, 11
[46] Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting
Falette-Puisieux, Manon
Nault, Jean-Charles
Bouattour, Mohamed
Lequoy, Marie
Amaddeo, Giuliana
Decaens, Thomas
Di Fiore, Frederic
Manfredi, Sylvain
Merle, Philippe
Baron, Aurore
Locher, Christophe
Pellat, Anna
Coriat, Romain
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[47] Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration
Alkadimi, Munaf
Lucero, Kana
Boyle, Lauren Diaz
Fierro, Maria Elena
Franklin, Kathleen
Nooruddin, Zohra
Mader, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
Ando, Yuwa
Kawaoka, Tomokazu
Kosaka, Masanari
Shirane, Yuki
Johira, Yusuke
Miura, Ryoichi
Murakami, Serami
Yano, Shigeki
Amioka, Kei
Naruto, Kensuke
Kosaka, Yumi
Uchikawa, Shinsuke
Kodama, Kenichiro
Fujino, Hatsue
Nakahara, Takashi
Ono, Atsushi
Murakami, Eisuke
Yamauchi, Masami
Okamoto, Wataru
Takahashi, Shoichi
Imamura, Michio
Chayama, Kazuaki
Aikata, Hiroshi
CANCERS, 2021, 13 (16)
[49] Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Zhang, Hui
Shao, Minghua
Tan, Binbin
Fu, Yin
Yuan
Chen, Hailei
CANCER RESEARCH, 2024, 84 (06)
[50] Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis
D'Alessio, Antonio
Weinmann, Arndt
Galle, Peter R.
Fulgenzi, Claudia Angela Maria
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Navaid, Musharraf
Naqash, Abdul Rafeh
Personeni, Nicola
Pressiani, Tiziana
Sharma, Rohini
Pinter, Matthias
Cortellini, Alessio
Rimassa, Lorenza
Pinato, David James
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

← 1 2 3 4 5 →